Is Buying Taro Pharmaceutical Industries LTD. Ordinary Share (NYSE:TARO) Here Good Idea?

April 16, 2018 - By Vivian Park

The stock of Taro Pharmaceutical Industries LTD. Ordinary Share (NYSE:TARO) registered an increase of 0.8% in short interest. TARO’s total short interest was 928,300 shares in April as published by FINRA. Its up 0.8% from 920,900 shares, reported previously. With 100,900 shares average volume, it will take short sellers 9 days to cover their TARO’s short positions. The short interest to Taro Pharmaceutical Industries LTD. Ordinary Share’s float is 8.71%.

The stock decreased 0.71% or $0.72 during the last trading session, reaching $100.13. About 6,764 shares traded. Taro Pharmaceutical Industries Ltd. (NYSE:TARO) has declined 17.38% since April 16, 2017 and is downtrending. It has underperformed by 28.93% the S&P500.

Taro Pharmaceutical Industries Ltd., a science pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. The company has market cap of $4.02 billion. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories. It has a 19.45 P/E ratio. The firm sells and distributes its products principally to drug industry wholesalers, drug store chains, mass merchandisers, healthcare institutions, and private pharmacies.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.